CRIS Current Research Information System

CASTAGNETTI, FAUSTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.695
AS - Asia 10.657
EU - Europa 7.413
SA - Sud America 616
AF - Africa 555
OC - Oceania 19
Continente sconosciuto - Info sul continente non disponibili 8
Totale 29.963
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.606
VN - Vietnam 2.911
SG - Singapore 2.863
CN - Cina 2.730
GB - Regno Unito 2.046
IT - Italia 1.004
DE - Germania 921
SE - Svezia 902
HK - Hong Kong 589
FR - Francia 505
IN - India 473
BR - Brasile 442
NL - Olanda 440
RU - Federazione Russa 405
KR - Corea 261
IE - Irlanda 255
UA - Ucraina 254
JP - Giappone 242
ZA - Sudafrica 173
EE - Estonia 136
FI - Finlandia 133
TG - Togo 124
CI - Costa d'Avorio 103
JO - Giordania 88
CH - Svizzera 82
BG - Bulgaria 78
AR - Argentina 65
PH - Filippine 65
ID - Indonesia 62
BD - Bangladesh 55
NG - Nigeria 53
CA - Canada 52
PL - Polonia 48
TH - Thailandia 48
AT - Austria 45
BE - Belgio 44
IQ - Iraq 39
TW - Taiwan 38
SC - Seychelles 37
TR - Turchia 37
EC - Ecuador 33
IR - Iran 28
MX - Messico 26
ES - Italia 25
GR - Grecia 23
PK - Pakistan 22
CL - Cile 21
AU - Australia 17
RO - Romania 15
UZ - Uzbekistan 15
MA - Marocco 14
VE - Venezuela 14
CO - Colombia 13
PY - Paraguay 13
SA - Arabia Saudita 13
AE - Emirati Arabi Uniti 12
LB - Libano 12
MY - Malesia 12
ET - Etiopia 11
KE - Kenya 10
IL - Israele 9
LT - Lituania 8
CZ - Repubblica Ceca 7
NP - Nepal 7
PE - Perù 7
EG - Egitto 6
TN - Tunisia 6
DK - Danimarca 5
GE - Georgia 5
PT - Portogallo 5
AL - Albania 4
DZ - Algeria 4
PS - Palestinian Territory 4
SK - Slovacchia (Repubblica Slovacca) 4
UY - Uruguay 4
A2 - ???statistics.table.value.countryCode.A2??? 3
BO - Bolivia 3
HN - Honduras 3
NO - Norvegia 3
RS - Serbia 3
SY - Repubblica araba siriana 3
TZ - Tanzania 3
XK - ???statistics.table.value.countryCode.XK??? 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
CY - Cipro 2
EU - Europa 2
GM - Gambi 2
HR - Croazia 2
JM - Giamaica 2
KZ - Kazakistan 2
LV - Lettonia 2
LY - Libia 2
NZ - Nuova Zelanda 2
OM - Oman 2
TT - Trinidad e Tobago 2
AO - Angola 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
Totale 29.942
Salva come PNG Salva come JPEG
Città #
Singapore 2.033
Southend 1.849
Ashburn 1.128
Fairfield 1.100
Chandler 869
Ho Chi Minh City 630
San Jose 615
Woodbridge 579
Hanoi 571
Wilmington 556
Hong Kong 548
Hefei 530
Houston 529
Seattle 513
Dong Ket 464
Beijing 394
Cambridge 393
Princeton 391
Ann Arbor 326
Boardman 257
Dublin 253
Seoul 233
Santa Clara 229
Lauterbourg 212
Tokyo 204
Nanjing 181
Bologna 166
Westminster 157
Padova 141
Los Angeles 136
New York 127
Lomé 124
Jacksonville 119
Dallas 118
Berlin 116
Helsinki 115
Abidjan 102
Buffalo 88
Da Nang 88
Milan 87
Amman 84
Haiphong 84
Jinan 82
Saint Petersburg 78
Sofia 78
Shenyang 75
Redondo Beach 74
Bern 73
Turin 73
Changsha 60
San Diego 60
Frankfurt am Main 59
Bengaluru 58
Nanchang 57
Falls Church 50
Abeokuta 49
Munich 49
Guangzhou 48
Hebei 48
Tianjin 48
Shanghai 47
São Paulo 47
Medford 44
Brussels 43
Council Bluffs 42
Jiaxing 41
Warsaw 41
Rome 40
Jakarta 38
Hangzhou 36
Zhengzhou 35
Biên Hòa 34
Bremen 33
Phoenix 33
Des Moines 32
Nuremberg 32
Mülheim 31
Orem 30
Redmond 30
Can Tho 29
Falkenstein 29
Florence 29
Norwalk 28
Hải Dương 27
London 25
Chengdu 24
Chicago 24
Ningbo 24
The Dalles 23
Brooklyn 22
Dearborn 22
Taizhou 22
Wuhan 22
Bangkok 21
Yubileyny 21
Baghdad 20
Mountain View 20
Johannesburg 19
Paris 19
Redwood City 19
Totale 19.756
Salva come PNG Salva come JPEG
Nome #
Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia 385
Efficacy and Clinical Outcome of Philadelphia (Ph) Positive Acute Lymphoblastic Leukemia (ALL) Patients Treated with Second Generation Tyrosine Kinase Inhibitors (TKIs): The Bologna Experience 351
IL-18 and VEGF-A trigger type 2 innate lymphoid cell accumulation and pro-tumoral function in chronic myeloid leukemia 343
Dual Src/Abl inhibitor SKI-606 binding mode in BCR-ABL kinase hypothesized on the basis of molecular docking studies 299
Binding Mode Of The Novel Dual SRC and ABL Inhibitor SKI-606 To The BCR-ABL Kinase As Predicted By Molecular Docking Studies 289
Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of patients with high risk, Philadelphia-positive, chronic myeloid leukaemia: a European LeukemiaNet study 279
ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia 273
A calpain-cleaved fragment of β-catenin promotes BCRABL1+ cell survival evoked by autophagy induction in response to imatinib 272
14-3-3 Binding and Sumoylation Concur to the Down-Modulation of β-catenin Antagonist chibby 1 in Chronic Myeloid Leukemia 265
Imatinib and pegylated human recombinant interferon-alpha2b in early chronic-phase chronic myeloid leukemia 252
Additional chromosomal abnormalities in Philadelphia-positive clone: adverse prognostic influence on frontline imatinib therapy: a GIMEMA Working Party on CML analysis 251
BCR-ABL1-associated reduction of beta catenin antagonist Chibby1 in chronic myeloid leukemia. 241
Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR) 233
Chromosome abnormalities additional to the Philadelphia chromosome at the diagnosis of chronic myelogenous leukemia: pathogenetic and prognostic implications. 228
Hyper-activation of Aurora kinase a-polo-like kinase 1-FOXM1 axis promotes chronic myeloid leukemia resistance to tyrosine kinase inhibitors 226
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 224
Ceftolozane-Tazobactam Treatment of Hypervirulent Multidrug Resistant Pseudomonas aeruginosa Infections in Neutropenic Patients 224
No influence of BCR-ABL1 transcript types e13a2 and e14a2 on long-term survival: results in 1494 patients with chronic myeloid leukemia treated with imatinib 220
Chibby drives β catenin cytoplasmic accumulation leading to activation of the unfolded protein response in BCR-ABL1+ cells 219
Chibby 1: A new component of β-catenin-signaling in chronic myeloid leukemia 219
A review and an update of European leukemianet recommendations for the management of chronic myeloid leukemia 218
Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: Molecular cytogenetic characterization and influence on TKIs therapy 214
The Inactivation of the Tumor Suppressor Genes CDKN2A/ARF by Genomic Deletions Frequently Occurs and Worsens Prognosis In Adult BCR-ABL1 Positive Acute Lymphoblastic Leukemia (ALL) Patients 207
Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib. 203
At the time of diagnosis, Ph cells from both chronic phase chronic myeloid leukemia and acute lymphoblastic leukemia patients already harbour BCR-ABL kinase domain mutations 201
The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia 199
BCR-ABL1 compound mutants: prevalence, spectrum and correlation with tyrosine kinase inhibitor resistance in a consecutive series of Philadelphia chromosome-positive leukemia patients analyzed by NGS 199
Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: Effects on response rate, toxicity and outcome 195
The BCR-ABL1 transcript type influences response and outcome in Philadelphia chromosome-positive chronic myeloid leukemia patients treated frontline with imatinib 194
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA 189
Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients 188
Philadelphia-positive patients who already harbour imatinib-resistant Bcr-Abl kinase domain mutations have a higher likelihood of developing additional mutations associated with resistance to second- or third-line tyrosine kinase inhibitors. 186
Treatment of Philadelphia-positive chronic myeloid leukemia with imatinib: importance of a stable molecular response 186
The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview 186
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 184
The 'Next-in-Cml' Study: A Prospective Multicenter Study of Deep Sequencing of the BCR-ABL1 Kinase Domain in Philadelphia Chromosome-Positive Patients with Non-Optimal Responses to Tyrosine Kinase Inhibitor Therapy 183
Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells 182
The EUTOS population-based registry: Incidence and clinical characteristics of 2904 CML patients in 20 European Countries 180
A review of the European LeukemiaNet recommendations for the management of CML 179
Contribution Of ABL Kinase Domain Mutations To Imatinib Resistance In Different Subsets Of Philadelphia-Positive Patients. By The GIMEMA Working Party On Chronic Myeloid Leukemia 179
Immune dysregulation associated with co-occurring germline CBL and SH2B3 variants 177
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report 176
Efficacy and clinical outcome of Philadelphia positive Acute Lymphoblastic Leukemia patients treated with second generation tyrosine kinase inhibitors (TKIS): the Bologna experience 175
Influence of additional cytogenetic abnormalities on the response and survival in late chronic phase chronic myeloid leukemia patients treated with imatinib: long-term results. 175
Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML. 174
Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia 174
Variant Philadelphia translocations: molecular-cytogenetic characterization and prognostic influence on frontline imatinib therapy, a GIMEMA Working Party on CML analysis. 173
Charlson comorbidity index and adult comorbidity evaluation-27 might predict compliance and development of pleural effusions in elderly chronic myeloid leukemia patients treated with dasatinib after resistance/intolerance to imatinib. 172
FOXM1 Transcription Factor: A New Component of Chronic Myeloid Leukemia Stem Cell Proliferation Advantage 171
Histone H3 covalent modifications driving response of BCR-ABL1+ cells sensitive and resistant to imatinib to Aurora kinase inhibitor MK-0457 170
Imatinib Mesylate Determines a High Frequency of Major Molecular Responses in Newly Diagnosed Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia on Behalf of the GIMEMA CML WP. 167
Cytoplasmic mutated nucleophosmin (NPM1) in blast crisis of chronic myeloid leukaemia. 166
The response to imatinib and interferon-alpha is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. 166
Nilotinib for the frontline treatment of Ph(+) chronic myeloid leukemia. 166
Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. 166
Arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life practice are predicted by the Systematic Coronary Risk Evaluation (SCORE) chart 166
Questions concerning tyrosine kinase-inhibitor therapy and transplants in chronic phase chronic myeloid leukaemia 165
Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia 164
Second-line treatment with dasatinib in patients resistant to imatinib can select novel inhibitor-specific BCR-ABL mutants in Ph+ ALL 163
Presence or the Emergence of a F317L BCR-ABL Mutation May Be Associated With Resistance to Dasatinib in Philadelphia Chromosome Positive Leukemia 162
Treatment-free remission in chronic myeloid leukemia patients treated front-line with nilotinib: 10-year followup of the GIMEMA CML 0307 study 161
FOXM1 Transcription Factor Is a Component of Beta Catenin Signaling in Hematopoietic Progenitors of Chronic Myeloid Leukemia 160
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison. 159
Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment 159
Ponatinib treatment in chronic myeloid leukemia cell lines targets aurora kinase A/FOXM1 axis 159
Leucemia mieloide cronica: terapia molecolare 158
Deep sequencing of the BCR-ABL kinase domain reveals a frequency of 35INS insertion/truncation higher than expected 158
In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants 157
Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/µl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs) 157
Deletionsof the derivative chromosome 9 do not influence the response and the outcomeof chronic myeloid leukemia in early chronic phase treated with imatinibmesylate: GIMEMA CML Working Party analysis 157
Low level mutations in the Bcr-Abl kinase domain may already be detected at diagnosis both in patients with Philadelphia-positive acute lymphoblastic leukemia and in patients with chronic phase chronic myeloid leukemia 157
Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival 156
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 156
Long-term follow-up of essential thrombocythemia in young adults: treatment strategies, major thrombotic complications and pregnancy outcomes. A study of 76 patients. 155
Low-level Bcr-Abl mutations are very rare in chronic myeloid leukemia patients who are in major molecular response on first-line nilotinib 153
Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy 152
Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study 151
Polo-like kinase-1, Aurora kinase A and WEE1 kinase are promising druggable targets in CML cells displaying BCR::ABL1-independent resistance to tyrosine kinase inhibitors 151
High Sensitivity Mutation Monitoring and Clonal Analysis by Ultra-Deep Amplicon Sequencing Uncover the Complexity of BCR-ABL Mutation Status in Philadelphia+ Patients Treated with Tyrosine Kinase Inhibitors 150
GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 150
Prospective assessment of NGS-detectable mutations in CML patients with non-optimal response: the NEXT-in-CML study 150
DNA hypermethylation promotes the low expression of pro-apoptotic BCL2L11 associated with BCR-ABL1 fusion gene of chronic myeloid leukaemia 149
Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. 149
Residual peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 149
Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey 149
Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. 148
One-Step Quantitative Molecular Approach for Detection of BCR/ABL1 Rearrangement and for Monitoring of Minimal Residual Disease in CML Patients: An Inter Laboratory Study 148
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors. 147
Bcr-Abl Positive Chronic Myeloid Disorders. Risk stratification Models, Prognostic Variables 145
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia 145
INTERMITTENT IMATINIB (INTERIM) TREATMENT IN PH+-CML ELDERLY PATIENTS IN STABLE COMPLETE CYTOGENETIC RESPONSE 145
Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib 145
Droplet digital PCR for the detection of second-generation tyrosine kinase inhibitor-resistant BCR::ABL1 kinase domain mutations in chronic myeloid leukemia 144
DNA methyltransferase 1 drives transcriptional down-modulation of β catenin antagonist Chibby1 associated with the BCR-ABL1 gene of chronic myeloid leukemia. 144
IDH2 somatic mutations in chronic myeloid leukemia patients in blast crisis. 144
Tyrosine kinase inhibitors in chronic myeloid leukaemia: Which, when, for whom? 143
Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series 141
High frequency of small insertions and deletions in the BCR-ABL Kinase Domain revealed by ultra-deep sequencing 141
Diagnosis and classification of the risk 140
Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications 140
Totale 18.555
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.664
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.664
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.130 0 0 0 0 0 0 0 0 0 103 218 809
2021/20223.217 305 86 239 290 326 198 59 218 159 223 526 588
2022/20233.603 412 564 195 432 260 261 143 190 586 98 303 159
2023/20241.052 47 153 62 101 77 260 66 61 42 65 63 55
2024/20254.376 116 692 381 312 519 219 272 108 46 536 267 908
2025/20269.554 1.045 1.070 1.005 740 1.091 505 916 511 1.977 694 0 0
Totale 30.593